Results 1 to 10 of about 19,013 (180)

Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer. [PDF]

Immunology
Conceptual ‘Crossroads Model’ linking Leishmania, thymic infection and immune dysregulation: an integrative model is proposed in which Leishmania infection disrupts thymic architecture and stromal–thymocyte interactions. These alterations converge to promote defective tolerance, increased autoimmune risk and a microenvironment permissive to malignant ...
Barros ABB, Leite GA, de Andrade AG, Reis MDDS, Cavalcante-Silva LHA, Lins MP.   +5 more
europepmc   +2 more sources

Visceral Leishmaniasis in Somalia: Diagnosis and Management of a Classic Case in a Resource-Limited Endemic Setting. [PDF]

Clin Case Rep
ABSTRACT Visceral Leishmaniasis (VL), a severe systemic neglected tropical disease (NTD) caused by Leishmania donovani complex protozoa, poses a significant public health threat, particularly in East Africa, where it is fatal if untreated. Somalia is known to be endemic, but the true burden and programmatic challenges are poorly documented due to long ...
Hussein AN, Ali AO, Ahmed RZ, Abdirahman SM, Abdiwahab AD.   +4 more
europepmc   +2 more sources

Factors Associated With the Emergence and Spread of Visceral Leishmaniasis in the State of São Paulo, Brazil. [PDF]

Zoonoses Public Health
ABSTRACT Introduction Visceral leishmaniasis (VL), once considered a rural disease in Brazil, has progressively urbanised, particularly in the state of São Paulo (SSP), where the first urban cases emerged after the detection of the vector Lutzomyia longipalpis in 1997.
de Camargo-Neves VLF, Werneck GL.
europepmc   +2 more sources

Tegumentary Leishmaniasis Associated With Immune Reconstitution in an HIV Patient-A Case Report. [PDF]

Parasite Immunol
ABSTRACT HIV‐associated Immune Reconstitution Inflammatory Syndrome (IRIS) may significantly alter the immunopathological presentation of American Tegumentary Leishmaniasis (ATL), occasionally causing paradoxical clinical exacerbations. We report the long‐term follow‐up of a 39‐year‐old female coinfected with HIV and disseminated mucocutaneous ...
Xavier MB, Gomes CMC, Sousa RCM, Ishikawa EAY, Brito EB, Müller SFR, Fontes LDS, Brito JAGSM, Alcantara LDS, Corbett CEP.   +9 more
europepmc   +2 more sources

Brain Involvement in Leishmaniasis. [PDF]

Cell Biochem Funct
ABSTRACT Leishmaniasis is a neglected tropical disease caused by infection with the protozoan parasite Leishmania and it is a significant global health problem. The disease has a wide clinical spectrum, from tegumentary leishmaniasis (TL) that encompasses cutaneous (CL), mucosal (ML) and cutaneous‐diffuse (CDL) forms, to the potentially fatal systemic ...
Freitas CS, Coelho EAF, Christodoulides M.   +2 more
europepmc   +2 more sources

Visceral Leishmaniasis

Infectious Disease Clinics of North America, 2012
Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages. It is among the most neglected infectious diseases. Classical manifestations of VL include chronic fever, hepatosplenomegaly, and pancytopenia. Most cases can be detected through serologic and molecular testing.
van Griensven, J., Diro, E.
  +6 more sources

Immunity to Visceral Leishmaniasis [PDF]

Journal of Tropical Medicine, 2012
Peer ...
Ali, Nahid Ben, Mekuria, Asrat Hailu, Requena Rolania, José María, Engwerda, Christian R.   +3 more
openaire   +7 more sources

Immunobiology of visceral leishmaniasis [PDF]

Frontiers in Immunology, 2012
Visceral leishmaniasis (VL), commonly known as kala-azar, is caused by Leishmania donovani and Leishmania infantum (Leishmania chagasi in the Americas). These Leishmania species infect macrophages throughout the viscera, and parasites are typically found in the spleen, liver, and bone marrow.
Kumar, Rajiv, Nylén, Susanne
openaire   +3 more sources

Diagnosis of visceral leishmaniasis [PDF]

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2011
Leishmaniasis is a vector-borne disease with up to 350 million people at risk of infection worldwide. Among its different clinical manifestations, visceral is the most severe form. Since clinical features of visceral leishmaniasis (VL) mimic several other common diseases, accurate diagnosis is crucial as the treatment is associated with significant ...
Pankaj, Srivastava, Anand, Dayama, Sanjana, Mehrotra, Shyam, Sundar   +3 more
openaire   +2 more sources

Treatment of visceral leishmaniasis

Journal of Global Infectious Diseases, 2010
The available treatment options for visceral leishmaniasis (VL) have problems relating to efficacy, adverse effects and cost, making treatment a complex issue. We review the evidence relating to the different methods of treatment in relation to - efficacy and toxicity of the drugs in different areas of the world; ability to monitor side effects, length
E M Moore, D N Lockwood
openaire   +4 more sources